yesterday's cal l@8 20 am - ) "SPY - 188.06 is 50 sma and 38.2% fib retracement Usually a bounce...but weak now.........I GOGO to the Home depot I .......INSM Pivots right here." ( I didnt take it)
Insmed chart is still a death cross....The SPY still sits there and we will quickly see if the MM have the INSM volume to reverse. Good Luck
Add Zachs ( who most know) to the hore list. Like Motley SA and Piper ,they are putting out this junk for their money people; Zachs = "This biopharma company has seen one positive and two negative estimate revisions over the past 30 days and its Zacks Consensus Estimate has moved down over the same time frame, suggesting there may be trouble down the road. "
Not surprised given I read the news. Sure the results on NTM were stellar ,but the changing of the timeline wording to "several months in negotiations ' MAY mean the agencies want more testing. Good Luck
Investor DD - change to the Investor presentation Feb 2014 Timeline by terry_insm • Feb 25, 2014
The investor materials presented on the Insmed website reflects the **possible ** change to the NTM timeline.
The current investor presentation dated Feb 2014. There is no doubt Insmed did this for a reason.
Potential time to launch (page 8) was changed from mid 2015 to 2015-2017 + (plus)
"Preparations are underway"
My ignore for the clowns is on but for those who invest this change is current. imho - there will be "additional work to be done ". Each investor can evaluate his or her own risk tolerance. If Insmed for the first time in their history releases data worthy of a filing,Institutions will fluctuate the trading to allow for a position Good Luck
Please Evelyn - go over and stay at invsrvillge. Those bds are useless with only pumping allowed.
fudfighter 234..investorvillage blasdp31 b-leagured and insmview is just a few of your identities.hubby nailed it
My post was from February when Insmed first let investors know the NTM results would need clarity and the timeline was indeed pushed out (2015-2017 +) from the mid 2015 hope of 2013.... The new presentation of May shows as you say 2015-16 timeline+ and yesterday the PR simply said "several months" before decision on the regulatory pathway in Europe AND the US would be known. This is NOT a filing or a launch date - it is a date when the company knows what to prepare for- a new trial or filing prep. I agree the breaktrru designation should be known shortly (covering rally and then a pullback -)). As you can see many didn't understand the PR yesterday and are baffled- they shouldn't be,Insmed has been telegraphing what they know. Good Luck
Today is short covering in the biotech sector. The market will resume after the weekend holiday - ) 1 trade
-Uncertainty is always bad for a stocks price, but will make for good trading.The MMs will take adv as I will YTD +90% have more fun
Looking at the results % of applicants, I doubt Insmed gets it. I hope they do- it would set up a trade. Have a great wkend, South o the Border ....
Nice work ladies! I'm back to trade!.he poster of the open option interest as a short hedge has it right - )
The chart is an obvious and I see my trade was deleted--Have more fun ! YTD +90% and short INSM - I love this stock! ............... Will trade tomorrow Surfs Up! Good Luck
Fockers! cover 3/4 - I put up my target when I went short but it was deleted .1/4 position still short, and yes they did go to get me... Manipulation !! YTD +97% , This is no doubt painful for many and I had a couple of winners this year I wished I had taken more off the table.."buy and hold is the worst way to invest in Bios - believe it ".On a positive note - the sentiment here is at a multiyear low- and accurate it has been... Good Luck
.With no fewer than 5 identities on this page fudfighter is angry! =boy - evelyn lol!! -Did the girls delete posts? respect others opinions ??
ok Mike, just saw that that post was deleted ..Insmed broke a trendline today signalling another leg down...
and normally I would trust the chart had it not been for the sneaky PR Friday..YTD+97% and some shorts to cover. Congrats on
Mannkind.............................. Good Luck ---
Sorry about my 19.79 sell call 4 trading days ago by terry_insm •Apr 7, 2014
(Trendline change strong reversal signal- I posted it 4 times)
disliked this post **18 ** (too bad you could have sold@ $20 )
Some action today by terry_insm • May 12, 2014 4:09 PM
disliked this post **21** (too bad you could have sold@16)
thats a good bet ) ......15.93 then ...Look its a Golden Cross ! ....(50 x200)
I subsequently posted the target,but wont now
Greg Wade ( phD) left Wedbush and his recc behind , but since it was a polarizing call ...... Greg went to work for Pharmacyclics .. a company I use to own. Dr Wade called for additional trialing of Arikayce and that Insmed did not /would not have the needed information from trialing the FDA demands. Now INSM is 5 bucks from his call ,but those that shorted after the results ( uhmm I blush) have done well. 19.79 to 11.87
- "Biotech sector has reset-Piper J $51 -who would believe such a thing ? by terry_insm • Apr 25, 2014 "
I blush .... MMs are doing simple trading as there are little shares and everyone is positioned Good Luck
Jun 6, 2014 05:40 AM # signal # trigger GLBuy 12:10 GL 3500k @12.27
Jun 11,2014 10:10 AM Just SOLD all ( 6 lots - 13.41 )
on the sidelines .... YTD +120%, I tried to tell ya..... Surfs up kids! .
Breakthrough status is in fact the same as fast track but with a vague "guidance" from the FDA to speed up approval. Some observers think the FDA is actually favoring too many candidates and thereby diluting its resources through expedited review programs, thus diluting its resources so much that in fact none of them will see much difference in the approval shortening time.
Also other agencies around the world may not accept the FDAs decision. Pharma agencies around the world are notoriously snobby.
-On the face of it, I think Arikayce should receive the status,but if it doesn't , I really don't think its that big a deal. Traders will use it as an excuse to move it up or down.
-IMHO - the regulatory pathway yet to be determined is more important. A mandated Phase3 trial will affect the company far more.
********** The FDA will not disclose information regarding sponsors who have been granted or denied breakthrough therapy designation. FDA will respond to breakthrough therapy designation requests within 60 days of receipt of the request. ---- Insmed does not have to say a word. - clever (or hidden in a PR coming? )).Everyone is positioned. I am on the sidelines.....we shall see. Good Luck -no trading,surfs up!